Ikonisys Announces the Completion of a Private Placement to Accelerate Its Commercial Development

Regulatory News:

Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO), a company specializing in the early and accurate detection of cancer with a unique and fully-automated solution for medical diagnostic labs (the “Issuer”), announced today that it raised €0.5m, via a private placement with Italian investors and its shareholder Cambria Equity Partners, in order to enlarge its international shareholders base and strengthen its financial resources, to secure well advanced commercial opportunities with prospects in the United States and in Europe.

The net proceeds of this issue, amounting to €0.5m, should provide the Issuer with additional resources to support its development in the framework of its first commercial success, notably by financing the working capital needs of the Issuer and by increasing its financial visibility. The new funds will also support the continued technological development of the Ikoniscope platform, particularly in the innovative field of Circulating Tumor Cells (CTC).

Legal terms of the Capital Increase

The implementation of this capital increase, carried out with cancellation of shareholders' subscription rights through a private placement, was approved by the Board of Directors of the Issuer at its meeting held on June 14, 2023 (the "Capital Increase").

The new shares will be issued on the basis of the eighth resolution of the Issuer's shareholders' meeting held on June 16, 2022. The settlement-delivery of the new shares will take place on June 19, 2023.

The Capital Increase did not require the approval of a prospectus by the AMF.

Main terms of the Capital Increase

The Issuer has issued a total of 303,030 new ordinary shares, with a par value of €0.50 each, to a restricted circle of investors including Cambria Equity Partners (for approximately 10% of the funds raised), pursuant to article L. 411-2 1° of the French Monetary and Financial Code, in accordance with the 8^th resolution passed by its Annual General Meeting on June 16, 2022.

The issuance price of the new shares issued under the Capital Increase, equal to €1.65 per share, represents a discount of approximately 1% on the Ikonisys share price at the close of 14 June 2023.

Impact of the transaction in terms of liquidity risk management and financing horizon

As at December 31, 2022, and as mentioned in the annual financial statements published on April 29, 2023, the Issuer's consolidated cash position amounted to €93,985.